CMS Urged To Lift All Evidence-Development Restrictions On PET For Solid Tumors

Move to lift coverage-with-evidence-development restrictions is widely supported by industry, medical specialty societies and clinicians.

The National Oncologic PET Registry has successfully met the goal for which it was established and should be disbanded, the NOPR working group and others told CMS in response to an ongoing Medicare coverage analysis for positron emission tomography for diagnosing and managing solid tumors.

In comments due to the Medicare agency Oct. 12, the NOPR working group encouraged CMS to remove all remaining coverage-with-evidence-development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.

Digital Health Roundup: Autonomous Robots, Medtronic’s Surgeon School, Sleep & FDA Rules

In this week's Digital Health Roundup, Medtech Insight's team discusses progress on autonomous surgery, Medtronic's new partnership with IRCAD, FDA cybersecurity news, and C-suite interviews with OpenWater, Flow Neuroscience and EnsoData.

Whoops! FDA Says Company Marketed Unauthorized Device. The Company Says The FDA Is Wrong

 

A recent FDA warning letter claims a Boston firm that specializes in wearable technology marketed a blood pressure device without agency approval. The company rejects the assertion and says the agency is out of step with federal law.